Spots Global Cancer Trial Database for Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Official Title: A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations
Study ID: NCT02607813
Study Description
Brief Summary: A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Massachusetts General Hospital MGH Cancer Center, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center SC - LXH254X2101, New York, New York, United States
UT M.D Anderson Cancer Center SC - LXH254X2101, Houston, Texas, United States
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Paris Cedex 10, , France
Novartis Investigative Site, Toulouse, , France
Novartis Investigative Site, Heidelberg, , Germany
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Modena, MO, Italy
Novartis Investigative Site, Napoli, , Italy
Novartis Investigative Site, Chuo ku, Tokyo, Japan
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Groningen, , Netherlands
Medical Oncology, Erasmus MC, Rotterdam, , Netherlands
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Zuerich, , Switzerland
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
